Abiopharma

🔍 Whittle John (Executive)

Company: Fortinet, Inc. (FTNT)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Acquired 1,608 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 94,069.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 1,827 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 95,896.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 1,137 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 97,033.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,309 shares of Common Stock at $86.29 per share (Direct)
  Date: 2026-05-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 94,724.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 1,608 shares of Restricted Stock Units (Derivative)
  Date: 2026-05-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 4,825.00 | transaction_form_type: 4 | Footnotes: F3, F1, F4, F5
• Sold 1,827 shares of Restricted Stock Units (Derivative)
  Date: 2026-05-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 12,788.00 | transaction_form_type: 4 | Footnotes: F3, F1, F6, F5
• Sold 1,137 shares of Restricted Stock Units (Derivative)
  Date: 2026-05-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 12,515.00 | transaction_form_type: 4 | Footnotes: F3, F1, F7, F5

Footnotes:

• F1: Vesting of restricted stock units ("RSUs") previously granted to the Reporting Person.
• F2: Exempt transaction pursuant to Section 16b-3(e) - payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. All of the shares reported as disposed of in this Form 4 were relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of RSUs.
• F3: Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement.
• F4: 25% of the RSUs vested on February 1, 2024, and the remaining 75% of the RSUs will vest in equal installments on each quarterly anniversary thereafter, until such time as the RSUs are 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person upon settlement.
• F5: RSUs do not expire; they either vest or are canceled prior to the vesting date.
• F6: 25% of the RSUs vested on February 1, 2025, and the remaining 75% of the RSUs will vest in equal installments on each quarterly anniversary thereafter, until such time as the RSUs are 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person upon settlement.
• F7: 25% of the RSUs vested on February 1, 2026, and the remaining 75% of the RSUs will vest in equal installments on each quarterly anniversary thereafter, until such time as the RSUs are 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person upon settlement.